Samsung Biologics, a South Korean biopharmaceutical firm, has signed a deal to manufacture Moderna's COVID-19 vaccine at its local factory.
Samsung Biologics, under the agreement, will provide Moderna with contract manufacturing organization (CMO) services for its mRNA vaccine, which implies that some of the Moderna vaccine can be manufactured in South Korea. The two sides signed the contract on Saturday during a South Korea-U.S. vaccine partnership event held in Washington, DC, with President Moon Jae-in attendance, reports Yonhap news agency.
‘New deal is expected to improve stable and speedy supply of the Moderna's COVID-19 vaccine in South Korea.’
Read More..
Also present were John Rim, CEO of Samsung Biologics, and his Moderna counterpart Stephane Bancel, along with Stanley Erck, CEO of Novavax, another American vaccine production company. Read More..
The deal is expected to contribute to the stable and speedy supply of the Moderna vaccine in South Korea, according to Moon's office, Cheong Wa Dae.
Moon pledged his government's full support for the vaccine developers and manufacturers, citing the nation's goal of emerging as a "global vaccine production hub."
Moon pointed out that he and U.S. President Joe Biden agreed to establish a comprehensive global vaccine partnership between the allies during their summit talks the previous day.
The president described it as a "vaccine alliance" to help combine the original technologies of the U.S. and the drug production capability of South Korea.
Advertisement
Moderna also signed a memorandum of understanding (MOU) with South Korea's Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
Advertisement
South Korea's National Institute of Health also signed an MOU with Moderna on strengthening cooperation on research into infectious diseases.
Source-IANS